Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12
Source : https://www.exphem.org/article/S0301-472X(22)00700-7/fulltext
Diffuse large B-cell lymphoma (DLBCL) is an essentially heterogeneous subgroup of aggressive B-cell lymphomas. To categorize the entity based on the "cell-of-origin" (COO), gene expression profiling studies have classified DLBCL...
Conclusion: Since a limited number of ABC-DLBCL cell lines are available to date, TMD12 cells might provide a useful tool in the search for novel druggable targets of this intractable lymphoma.
MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)
Source : https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22)01570-1/pdf
Context: Covalent Bruton's Tyrosine Kinase (BTK) inhibitors (BTKi) have transformed the management of relapsed mantle cell lymphoma (MCL), but many patients will require additional treatment. Pirtobrutinib is a highly selective,...
Objective: Determine whether pirtobrutinib is superior to investigator's choice of covalent BTKi in patients with previously treated, BTKi-naïve MCL.
Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36145624/
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown. In this study, we found...
Conclusion: Collectively, our findings addressed a novel molecular basis underlying Ibrutinib-induced endothelial cell dysfunction and suggested the potential application of Ibrutinib to treat angiogenesis-dependent cancers.
NFkB Pathway and Hodgkin Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36140254/
The tumor cells that drive classical Hodgkin lymphoma (cHL), namely, Hodgkin and Reed-Sternberg (HRS) cells, display hallmark features that include their rareness in contrast with an extensive and rich reactive...
Conclusion:Targeting this complex pathway directly (NIK inhibitors) or indirectly (PIM, BTK or NOTCH) remains a challenge with potential therapeutic relevance. Nodular predominant HL (NLPHL), a distinct and rare HL subtype, shows a strong NFkB activity signature because of mechanisms that differ from those observed in cHL, which is discussed in...
Management of front line chronic lymphocytic leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36125035/
1 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Duesseldorf and German CLL Study Group, University of Cologne, Cologne, Germany. Treatment options with targeted agents have...
Relevance: We here discuss latest trial data and propose a treatment algorithm for frontline treatment of CLL according to fitness and relevant genetic risk factors like IGHV mutational status and TP53 aberrations.